Aramchol (C20-FABAC), also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid. It reduces ex vivo cholesterol crystallization in native human bile and dissolves pre-formed cholesterol crystals in a dose-dependent manner.

Three months' administration of the fatty acid-bile acid conjugate Aramchol is significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease[1].

Performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n = 20/group). The main end point was the difference between groups in the change in liver fat content according to magnetic resonance spectroscopy. The secondary end points focused on the differences between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function[1].